Get the Stockscreener App
227.88
2.41%
-5.62
After Hours:
227.16
-0.72
-0.32%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $227.88, with a volume of 927.04K.
It is down -2.41% in the last 24 hours and down -11.98% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$233.50
Open:
$231.57
24h Volume:
927.04K
Relative Volume:
0.87
Market Cap:
$33.20B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
22.52
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
-5.11%
1M Performance:
-11.98%
6M Performance:
-16.62%
1Y Performance:
+3.46%
1-Day Range:
$227.87
$232.19
1-Week Range:
$227.87
$238.80
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
227.88 | 33.59B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
477.73 | 171.69B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
158.08 | 45.59B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.74 | 37.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
42.26 | 33.89B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Captrust Financial Advisors Increases Stake in ResMed Inc. - National Today
Captrust Financial Advisors Buys 27,565 Shares of ResMed Inc. $RMD - MarketBeat
Achmea Investment Management B.V. Decreases Stake in ResMed Inc. $RMD - MarketBeat
With global populations ageing, are ResMed shares a good buy today? - The Motley Fool Australia
Why Cochlear and ResMed shares could be strong buys - The Motley Fool Australia
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed Stock In Shambles: Down 6.7% With 5-Day Losing Streak - Trefis
Is Resmed Shares a Smart Addition to Your Investment Portfolio at This Time? - Bitget
ResMed (RMD) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Is Resmed Stock the Right Pick for Your Portfolio Now? - Yahoo Finance
Mirabella Financial Services LLP Purchases 5,562 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Stock Plummets 8.8% With 5-Day Losing Streak - Trefis
Short Interest in ResMed Rises 17.2% - National Today
ResMed Stock Slides -8.8% With A 5-Day Losing Spree - Trefis
Short Interest in ResMed Inc. (NYSE:RMD) Grows By 17.2% - MarketBeat
California Public Employees Retirement System Has $78.58 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed: Waiting For The Next Catalyst, Initiating With Hold Rating (NYSE:RMD) - Seeking Alpha
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Stifel reiterates Hold on ResMed stock, keeps $265 price target By Investing.com - Investing.com India
Aquatic Capital Management Boosts ResMed Stake by 106% - National Today
Aquatic Capital Management LLC Buys 12,642 Shares of ResMed Inc. $RMD - MarketBeat
What are analysts saying about ResMed, Downer, and Nuix shares? - The Motley Fool Australia
RMD SEC FilingsResmed 10-K, 10-Q, 8-K Forms - Stock Titan
ResMed CEO Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
ResMed Inc Stock (ISIN: AU000000RMD6) Faces Pressure Amid Share Price Pullback and Valuation Debate - AD HOC NEWS
Capital Impact Advisors LLC Boosts Holdings in ResMed Inc. $RMD - MarketBeat
Is It Time To Reconsider ResMed (RMD) After The Recent Share Price Pullback - Yahoo Finance
3 Reasons Not to Sleep on ResMed Stock - AOL.com
2Xideas AG Acquires 8,397 Shares of ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Landscape Capital Management L.L.C. Boosts Stake in ResMed Inc. $RMD - MarketBeat
Russell Investments Group Boosts Stake in ResMed - National Today
Mackenzie Financial Corp Trims Stock Position in ResMed Inc. $RMD - MarketBeat
Russell Investments Group Ltd. Has $30.85 Million Position in ResMed Inc. $RMD - MarketBeat
Bank of Montreal Can Sells 128,166 Shares of ResMed Inc. - National Today
Bank of Montreal Can Sells 128,166 Shares of ResMed Inc. $RMD - MarketBeat
ChartWatch ASX Scans: Whitehaven Coal, New Hope Corp, Yancoal, CSL, Charter Hall, Resmed, Seek, Zip Co. - Market Index
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Legal & General Group Plc Reduces ResMed Inc. Stake - National Today
Legal & General Group Plc Reduces Stake in ResMed Inc. - National Today
Schroder Investment Management Group Boosts Stake in ResMed Inc. - National Today
Is ResMed Stock Underperforming the Nasdaq? - Yahoo Finance
Schroder Investment Management Group Boosts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Legal & General Group Plc Has $262.29 Million Position in ResMed Inc. $RMD - MarketBeat
Is It Time To Reconsider ResMed (RMD) After Recent Share Price Pullback - simplywall.st
ChartWatch ASX Scans: Lynas Rare Earths, Finder Energy, Lindian Resources, Resmed, Treasury Wine Estates, Harvey Norman - Market Index
ResMed (RMD) Stock Trades Down, Here Is Why - Yahoo Finance
Hedge Fund and Insider Trading News: Bill Ackman, Stanley Druckenmiller, Ken Griffin, Caxton Associates, Braidwell LP, Rokos Capital Management, ResMed Inc (RMD), Accel Entertainment Inc (ACEL), and More - Insider Monkey
ResMed (NYSE:RMD) CEO Sells $1,252,890.73 in Stock - MarketBeat
Resmed Insider Sold Shares Worth $1,252,902, According to a Recent SEC Filing - marketscreener.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
2.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):